Small-Cell Lung Cancer Transformation in Patients with Pulmonary Adenocarcinoma: A Case Report and Review of Literature

Medicine (United States)

Volumn 95, Issue 6, 2016, Pages

  Jiang, Shi Yu ^a   Zhao, Jing ^a   Wang, Meng Zhao ^a   Huo, Zhen ^a   Zhang, Jing ^a   Zhong, Wei ^a   Xu, Yan ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; PEMETREXED; PLATINUM; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; CASE REPORT; DRUG RESISTANCE; FATALITY; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; SMALL CELL LUNG CARCINOMA; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEMETREXED; PLATINUM; QUINAZOLINES; SMALL CELL LUNG CARCINOMA;

EID: 84958233118     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002752     Document Type: Article

References (20)

1. Rossi A, Di Maio M. LUX-Lung: determining the best EGFR inhibitor in NSCLC? Lancet Oncol. 2015;16:118-119.
2. Ma AT, Chan WK, Ma ES, et al. Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinibresistant adenocarcinoma of the lung. Acta Oncol. 2012;51:557-559.
3. Watanabe S, Sone T, Matsui T, et al. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer. 2013;82:370-372.
4. van Riel S, Thunnissen E, Heideman D, et al. A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation. Ann Oncol. 2012;23:3188-3189.
5. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:r26-r75.
6. Morinaga R, Okamoto I, Furuta K, et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer. 2007;58:411-413.
7. Alam N, Gustafson KS, Ladanyi M, et al. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer. 2010;11:E1-E4.
8. Popat S, Wotherspoon A, Nutting CM, et al. Transformation to high grade neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;80:1-4.
9. Zakowski MF, Ladanyi M, Kris MG, et al. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 2006;355:213-215.
10. Norkowski E, Ghigna MR, Lacroix L, et al. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. J Thorac Oncol. 2013;8:1265-1271.
11. Mangum MD, Greco FA, Hainsworth JD, et al. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607-612.
12. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): A clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184-1197.
13. Walker GE, Antoniono RJ, Ross HJ, et al. Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBP-rP1 and 25.1. Oncogene. 2006;25:1943-1954.
14. Teicher BA. Targets in small cell lung cancer. Biochem Pharmacol. 2014;87:211-219.
15. DAngelo SP, Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther. 2010;10:1-10.
16. Fukui T, Tsuta K, Furuta K, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 2007;98:1714-1719.
17. Arrieta O, Villarreal-Garza C, Martinez-Barrera L, et al. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: A prospective cohort study. BMC Cancer. 2013;13:254-260.
18. Qin HF, Qu LL, Liu H, et al. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14:4205-4208.
19. Dowlati A, Wildey G. Defining subgroups of small-cell lung cancer. J Thorac Oncol. 2014;9:750-751.
20. Oser MG, Niederst MJ, Sequist LV, et al. Transformation from nonsmall-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16:e165-e172.